Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Procore Q3 2026 net loss narrows 50% to $4.59 million; Q3 2026 revenue rises 19% to $402.31 million

Procore Q3 2026 net loss narrows 50% to $4.59 million; Q3 2026 revenue rises 19% to $402.31 million

BitgetBitget2026/11/03 21:18
  • Procore Technologies’ third-quarter 2026 net loss narrowed 50% year over year to $4.59 million.
  • Revenue rose 19% to $402.31 million, while operating cash inflow increased 8% to $96 million.
  • The construction software provider acquired DroneDeploy to expand visual intelligence and AI capabilities, and made its AI digital coworkers generally available.
  • Full-year 2026 revenue is expected at $1.56 billion, representing growth of 17.7% to 17.9%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procore Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103221803) on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny

CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.

智通财经•2026/11/09 06:37
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny